Evozyne to develop synthetic proteins for Takeda gene therapies

By The Science Advisory Board staff writers

January 25, 2021 -- Molecular engineering company Evozyne has signed a strategic collaboration and license agreement with Takeda Pharmaceutical. The partnership's aim is to develop proteins that can be incorporated into next-generation gene therapies for genetic disorders within inborn errors of metabolism and lysosomal storage diseases.

Evozyne uses advanced computational and machine-learning methods in its evolution-based engineering process to create synthetic proteins with precision and efficiency. In partnership with Takeda, Evozyne will create novel protein sequences for gene therapies. At completion, Takeda will have the option to obtain an exclusive license to develop and commercialize the novel protein sequences as part of its gene therapy program.

Under the agreement, Evozyne is eligible to receive an upfront payment of an undisclosed amount and additional research, development, and regulatory milestone payments, as well as royalties on sales of any commercial products resulting from the collaboration.

Elektrofi, Takeda partner to advance plasma protein therapeutics
Biotechnology firm Elektrofi and Takeda Pharmaceuticals have partnered to advance high-concentration, low-viscosity protein therapeutics.
Takeda opens new cell therapy manufacturing facility
Takeda Pharmaceuticals said it has opened a new 24,000-sq-ft research and development (R&D) cell therapy manufacturing facility at its R&D headquarters...
Takeda, Twist partner on biologics discovery
Twist Bioscience and Takeda Pharmaceutical have formed a partnership for access to Twist's proprietary phage display libraries for the discovery of antibodies...
Carmine, Takeda use extracellular vesicles for rare disease gene therapies
Carmine Therapeutics has signed a research collaboration agreement with Takeda Pharmaceutical to develop gene therapies for rare diseases.

Copyright © 2021 scienceboard.net

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter